NCT00136292View on ClinicalTrials.gov

Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 24, 2005

Primary Completion Date

August 1, 2006

Study Completion Date

August 9, 2006

Conditions
Gram-positive Bacterial Infections
Interventions
DRUG

daptomycin

Trial Locations (3)

64108

Children's Mercy Hospitals and Clinics, Kansas City

72202

University of Arkansas for Medical Sciences, Little Rock

75390

University of Texas Southwestern, Dallas

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00136292 - Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics | Biotech Hunter | Biotech Hunter